3)- Stavroula A Paschou, Evanthia Kassi, Theodora Psaltopoulou. Hyponatraemia in patients on immune checkpoint inhibitors.Therapeutic advances in endocrinology and metabolism. 2022, 13: 20420188221136755
4)- Liliane Mendonça, Bárbara Antunes, Joana Rigor, Daniela Martins-Mendes, Matilde Monteiro-Soares. Characterizing palliative care needs in people with or at risk of developing diabetic foot ulcers.Therapeutic advances in endocrinology and metabolism. 2022, 13: 20420188221136770
5)- Felix Grabherr, Christoph Grander, Maria Effenberger, Julian Schwärzler, Herbert Tilg. MAFLD: what 2 years of the redefinition of fatty liver disease has taught us.Therapeutic advances in endocrinology and metabolism. 2022, 13: 20420188221139101
6)- Alice A White, Ashleigh Lin, Xander Bickendorf, Blake S Cavve, Julia K Moore, Aris Siafarikas, Deborah H Strickland, Jonatan Leffler. Potential immunological effects of gender-affirming hormone therapy in transgender people - an unexplored area of research.Therapeutic advances in endocrinology and metabolism. 2022, 13: 20420188221139612
8)- Eda Kaya, Yusuf Yilmaz. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease.Therapeutic advances in endocrinology and metabolism. 2022, 13: 20420188221139650
10)- Bangjiaxin Ren, Ming Chen. Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis.Therapeutic advances in endocrinology and metabolism. 2022, 13: 20420188221142450
11)- Ángela Rojas, Carmen Lara-Romero, Rocío Muñoz-Hernández, Sheila Gato, Javier Ampuero, Manuel Romero-Gómez. Emerging pharmacological treatment options for MAFLD.Therapeutic advances in endocrinology and metabolism. 2022, 13: 20420188221142452